Fortress Biotech Sells PRV for $205M After ZYCUBO Approval
Cyprium Therapeutics (Fortress Biotech subsidiary) just signed a deal to sell its Rare Pediatric Disease Priority Review Voucher for $205M after FDA approval of ZYCUBO for Menkes disease.
/ 1659 items
#XY↓
Allurion's Smart Capsule Wins FDA Approval: A Swallowable Path to Lasting, Muscle-Sparing Weight Loss
Allurion Technologies gets FDA approval for its easy, non-surgical Allurion Smart Capsule – a swallowable gastric balloon that helps people lose weight safely without daily meds or surgery.
Enhabit to Go Private: Acquired by Kinderhook in $1.1 Billion Deal
Enhabit agrees to be bought by private equity firm Kinderhook for $1.1B in cash. Stockholders get $13.80/share—a nice premium—and the company stays focused on long-term care growth.
Gossamer Lung Disease Drug Misses Main Goal in Big Trial – But Shows Real Hope for Sickest Patients
Gossamer Bio’s seralutinib narrowly missed its Phase 3 target for pulmonary arterial hypertension, yet delivered strong benefits in higher-risk patients. Company still plans FDA talks.
InMode Ends Sale Talks: No Good Offers Found
InMode has stopped its review of buyout or merger proposals after deciding none were good enough for shareholders.
Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal to Boost Cancer Treatment Options
Gilead Sciences announces acquisition of Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy anito-cel for multiple myeloma patients, with deal expected to close in Q2 2026.